-1.0%
NCLH vs MRNA
+945.0%
-946.0%
-43.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +6.8% | +13.1% | -6.3% | +6.5% |
| 7D | +15.8% | +20.6% | -4.8% | +15.4% |
| 30D | +25.1% | +27.1% | -2.1% | +24.5% |
| 3M | -7.3% | +353.4% | -360.7% | -12.1% |
| 6M | +8.1% | +446.3% | -438.1% | -3.9% |
| YTD | -16.7% | +776.2% | -792.8% | -34.0% |
| 1Y | -1.0% | +987.9% | -988.9% | -23.7% |
| All | -1.0% | +945.0% | -946.0% | -23.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling